1. 18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review
- Author
-
David M. Schuster, Stephen B. Camper, Catriona M. Turnbull, Jason A. Efstathiou, Andrew Scarsbrook, Andy Kenwright, and Soroush Rais-Bahrami
- Subjects
Biochemical recurrence ,Cancer Research ,PET-CT ,medicine.medical_specialty ,Prostate cancer ,Prostatectomy ,business.industry ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Review Article ,medicine.disease ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,Systematic review ,medicine.anatomical_structure ,Oncology ,Prostate ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Prospective cohort study ,business - Abstract
Background A systematic literature review of the performance of 18Fluorine-fluciclovine PET/CT for imaging of men with recurrent prostate cancer was performed. Methods Scientific literature databases (MEDLINE, ScienceDirect and Cochrane Libraries) were searched systematically during Oct 2020 using PRISMA criteria. No limit was put on the date of publication. Prospective studies reporting a patient-level 18F-fluciclovine detection rate (DR) from ≥25 patients with recurrent prostate cancer were sought. Proceedings of relevant meetings held from 2018 through Oct 2020 were searched for abstracts meeting criteria. Results Searches identified 321 unique articles. In total, nine articles (six papers and three conference abstracts), comprising a total of 850 patients met inclusion criteria. Most studies (n = 6) relied on ASTRO-Phoenix Criteria, EAU-ESTRO-SIOG, and/or ASTRO-AUA guidelines to identify patients with biochemical recurrence. Patients’ PSA levels ranged from 0.02–301.7 ng/mL (median level per study, 0.34–4.10 ng/mL [n = 8]). Approximately 64% of patients had undergone prostatectomy, but three studies focused solely on post-prostatectomy patients. Adherence to imaging protocol guidelines was heterogeneous, with variance seen in administered activity, uptake and scan times. Overall patient-level DR varied between studies from 26% to 83%, with 78% of studies reporting a DR > 50%. DR was proportional to PSA, but even at PSA n = 7) ranged from 18% to 78% and extra-prostatic rates (n = 6) from 8% to 72%. Pelvic node and bone lesion DR ranged from 8% to 47% and 0% to 26%, respectively (n = 5). 18F-Fluciclovine PET/CT was shown to impact patient management and outcomes. Two studies reported 59–63% of patients to have a management change post-scan. A further study showed significant increase in failure-free survival following 18F-fluciclovine-guided compared with conventional imaging-guided radiotherapy planning. Conclusions 18F-Fluciclovine PET/CT shows good performance in patients with recurrent prostate cancer leading to measurable clinical benefits. Careful adherence to recommended imaging protocols may help optimize DR.
- Published
- 2021